References and Publications

Invited Publications

• Kawabe, T: Compounds that Abrogate the G2 Checkpoint. In Checkpoint Responses in Cancer Therapy. Dai, Wei(Ed.), Humana Press, 2008: 117-133.
• Kawabe, T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004 3: 513-519.

Peer-reviewed Publications

• Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. Clin Cancer Res 2011; 17: 3431-3442
• Sha, S-K, Sato, T, Kobayashi, H, Ishigak, M, Yamamoto S, Sato H, Takada A, Nakajyo S,Mochizuki Y, Friedman, JM, Cheng F-C, Okura T, Kimura R, Kufe DW, VonHoff DD, and Kawabe, T: Cell-cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol. Cancer Ther. 2007 6: 147-153.
• Sha, S-K, Sato, T, Kobayashi, H, Ishigak, M, Yamamoto S, Sato H, Takada A, Nakajyo S,Mochizuki Y, Friedman, JM, Cheng F-C, Okura T, Kimura R, Kufe DW, VonHoff DD, and Kawabe, T: Cell-cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol. Cancer Ther. 2007 6: 147-153.
• Kawabe T, Suganuma M, Ando T, Kimura M, Hori H, and Okamoto T: Cdc25C interacts with PCNA at G2/M transition. Oncogene, 21:1717-1726, 2002.
• Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, and Okamoto T: Involvement of the interaction between p21 and PCNA for the maintenance of G2/M arrest after DNA damage. J Biol Chem, 276(46), 42971-42977, 2001
• Suganuma M, Kawabe T, Hori H, Funabiki T, and Okamoto T: Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res, 59, 5887-5891, 1999

Abstracts

• Yamamoto S, Sato T, Hasegawa Y, Sato H, Ishigaki M, Suganuma M, Kufe D, VonHoff D, and KawabeT: CBP501 increases DNA damage induced by bleomycin and cisplatin. AACR Meeting Abstracts #1823, Apr 2009.
• Wong BY, Shapiro GI, Gordon MS, Borad MJ, Eder JP, Tibes R, Mendelson DS, Wasserman E, Kawabe T, and Sharma S: Phase I studies of CBP501, a novel G2 checkpoint abrogator, alone and combined with cisplatin (CDDP) in advanced solid tumor patients (pts). J Clin Oncol 26: 2008 (May 20 suppl; abstr 2528).
• Gordon M, Eder J, Mendelson D, Wasserman E, Sutherland W, Kawabe T, and Shapiro G: CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors. Eur J Cancer Suppl 2006. 4107 18th EORTC-NCI-AACR, Prague (November 7-10, 2006) Abstract 346.